TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: Results and prognostic factor analysis

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1706-1713

  Feldman, Darren R ^a   Sheinfeld, Joel ^a   Bajorin, Dean F ^a   Fischer, Patricia ^a   Turkula, Stefan ^a   Ishill, Nicole ^a   Patil, Sujata ^a   Bains, Manjit ^a   Reich, Lilian M ^a   Bosl, George J ^a   Motzer, Robert J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHORIONIC GONADOTROPIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; INFECTION; LUNG HEMORRHAGE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; RETREATMENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; PROGNOSIS; RETREATMENT; SALVAGE THERAPY;

EID: 77950466810     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.1561     Document Type: Article

References (19)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
3. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
4. Kondagunta GV, Bacik J, Donadio A, et al: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549-6555, 2005
5. Loehrer PJ, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998 (Pubitemid 28309047)
6. Einhorn LH, Williams SD, Chamness A, et al: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340-348, 2007 (Pubitemid 47124134)
7. Kondagunta GV, Bacik J, Sheinfeld J, et al: Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25:85-90, 2007 (Pubitemid 350003055)
8. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
9. Beyer J, Stenning S, Gerl A, et al: High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with nonseminomatous germ-cell tumors: A matched-pair analysis. Ann Oncol 13:599-605, 2002 (Pubitemid 34461144)
10. Rick O, Beyer J, Kingreen D, et al: High-dose chemotherapy in germ cell tumours: A large single centre experience. Eur J Cancer 34:1883-1888, 1998
11. Beyer J, Kramar A, Mandanas R, et al: High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645, 1996 (Pubitemid 26329647)
12. Lotz JP, Bui B, Gomez F, et al: Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation: Results of the phase II multicentric TAXIF trial. Ann Oncol 16:411-418, 2005 (Pubitemid 40458317)
13. Margolin KA, Doroshow JH, Frankel P, et al: Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant 11:903-911, 2005 (Pubitemid 41645643)
14. Shamash J, Stebbing J, Powles T, et al: Germcell tumors. N Engl J Med 357:1771-1772, 2007
15. Motzer RJ, Mazumdar M, Sheinfeld J, et al: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173-1180, 2000 (Pubitemid 30159833)
16. Jathavedam A, Feldman DR, Ishill N, et al: Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol Blood Marrow Transplant 14:595-600, 2008 (Pubitemid 351494750)
17. National Comprehensive Cancer Network: The NCCN Clinical Practice Guidelines in Oncology Testicular Cancer (V.I. 2010). http://www.nccn.org/index. asp
18. Lorch A, Beyer J, Mollevi C, et al: Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients. J Clin Oncol 27:242s, 2009 (suppl; abstr 5030)
19. Korkola J, Houldsworth J, Feldman DR, et al: Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 27:5240-5247, 2009